首页> 外国专利> IDENTIFICATION OF A NEW MOLECULAR FACTOR FOR EARLY DIAGNOSIS OF UROTHELIAL CARCINOMA OF THE BLADDER

IDENTIFICATION OF A NEW MOLECULAR FACTOR FOR EARLY DIAGNOSIS OF UROTHELIAL CARCINOMA OF THE BLADDER

机译:膀胱尿路上皮癌早期诊断的新分子因子的鉴定

摘要

The identification is disclosed of a new molecular factor for the early diagnosis of urothelial carcinoma of the bladder. HtrA1 is a molecule that is produced mainly by the urothelium of the bladder, both in physiological and inflammatory pathologies, such as cystitis, whereas it is absent in the urothelial layer of the neoplastic bladder mucosa, regardless of cancer grade and level. By means of Western Blotting two forms of HtrA1 were identified, both in bladder tissue and urine, the native 50 kDa form and the autocatalytic 38 kDa form. The 38 kDa form is significantly underexpressed in tumoral tissues compared with normal tissues and concentration of the 50 kDa form in urine is significantly higher in patients affected by bladder cancer compared to healthy subjects and subjects with cystitis. Therefore, the evaluation of tissutal and urinary HtrA1 levels can be a specific marker of urothelial carcinoma of the bladder.
机译:公开了用于早期诊断膀胱尿路上皮癌的新分子因子的鉴定。 HtrA1是一种分子,主要在生理和炎症病理(例如膀胱炎)中由膀胱尿路上皮产生,而在肿瘤膀胱粘膜的尿路上皮层中不存在,无论癌症的级别和水平如何。通过Western印迹,鉴定了两种形式的HtrA1,在膀胱组织和尿液中均是天然的50kDa形式和自催化的38kDa形式。与正常组织相比,在肿瘤组织中38 kDa形式的表达明显不足,并且在膀胱癌影响的患者中尿液中50 kDa形式的浓度显着更高。因此,组织和尿液中HtrA1水平的评估可能是膀胱尿路上皮癌的特异性标志物。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号